预约演示
更新于：2025-07-15
Teicoplanin
替考拉宁
更新于：2025-07-15
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)临床前 |
特殊审评孤儿药 (美国)、孤儿药 (欧盟) |
登录后查看时间轴
关联
37
项与 替考拉宁 相关的临床试验NCT06818565
Comparison of Efficacy and Safety of Ceftazidime Avibactam Versus Extended Infusions of High Dose Meropenem in Patients of ACLF With Nosocomial Infections.
NCT06426212
Use of Teicoplanin on a Three-weekly Administration in the Complex Outpatient Macroactivity Regimen of Infectious Diseases Unit in the Alessandro Manzoni Hospital (Lecco, Italy)
EUCTR2023-000005-12-IT
An open-label study to evaluate the safety and tolerability of inhaled Teicoplanin in the treatment of Staphylococcus aureus (including mrsa) infections in CYSTIC FIBROSIS PATIENTS - study to evaluate the safety of inhaled Teicoplanin in the treatment of Stafilococco infections
100 项与 替考拉宁 相关的临床结果
登录后查看更多信息
100 项与 替考拉宁 相关的转化医学
登录后查看更多信息
100 项与 替考拉宁 相关的专利（医药）
登录后查看更多信息
4,289
项与 替考拉宁 相关的文献（医药）2025-12-31Emerging Microbes & Infections
Genomic islands and molecular mechanisms relating to drug-resistance in
Clostridioides
(
Clostridium
)
difficile
PCR ribotype 176
Article
作者: Soltesova, Anna ; Pituch, Hanna ; Kuijper, Ed ; Balikova Novotna, Gabriela ; Brajerova, Marie ; Prasad, Suhanya ; Novakova, Elena ; Zikova, Jaroslava ; Demay, Fanny ; Kovarovic, Vojtech ; Krutova, Marcela ; Smits, Wiep Klaas
OBJECTIVES:
To analyse characteristics of Clostridioides difficile PCR ribotype 176 clinical isolates from Poland, the Czech Republic and Slovakia with regard to the differences in its epidemiology.
METHODS:
Antimicrobial susceptibility testing and whole genome sequencing were performed on a selected group of 22 clonally related isolates as determined by multilocus variable-number tandem repeat analysis (n = 509). Heterologous expression and functional analysis of the newly identified methyltransferase were performed.
RESULTS:
Core genome multilocus sequence typing found 10-37 allele differences. All isolates were resistant to fluoroquinolones (gyrA_p. T82I), aminoglycosides with aac(6')-Ie-aph(2'')-Ia in six isolates. Erythromycin resistance was detected in 21/22 isolates and 15 were also resistant to clindamycin with ermB gene. Fourteen isolates were resistant to rifampicin with rpoB_p. R505K or p. R505K/H502N, and five to imipenem with pbp1_p. P491L and pbp3_p. N537K. PnimBG together with nimB_p. L155I were detected in all isolates but only five were resistant to metronidazole on chocolate agar. The cfrE, vanZ1 and cat-like genes were not associated with linezolid, teicoplanin and chloramphenicol resistance, respectively. The genome comparison identified six transposons carrying antimicrobial resistance genes. The ermB gene was carried by new Tn7808, Tn6189 and Tn6218-like. The aac(6')-Ie-aph(2'')-Ia were carried by Tn6218-like and new Tn7806 together with cfrE gene. New Tn7807 carried a cat-like gene. Tn6110 and new Tn7806 contained an RlmN-type 23S rRNA methyltransferase, designated MrmA, associated with high-level macrolide resistance in isolates without ermB gene.
CONCLUSIONS:
Multidrug-resistant C. difficile PCR ribotype 176 isolates carry already described and unique transposons. A novel mechanism for erythromycin resistance in C. difficile was identified.
2025-09-01JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES
LC-MS/MS analysis of five antibiotics in dried blood spots for therapeutic drug monitoring of ICU patients
Article
作者: Song, Danfei ; Qian, Shijing ; Zhang, Sha ; Li, Jie ; Qi, Zhan ; Ye, Xiancheng
In the intensive care unit (ICU), optimizing antimicrobial therapy through Therapeutic Drug Monitoring (TDM) can significantly improve patient outcomes. We developed and validated a DBS method for the simultaneous quantification of five antibiotics commonly used in ICUs, namely imipenem, meropenem, tigecycline, teicoplanin, and vancomycin. Dried blood spots (DBS) were prepared by spotting 30 μL of blood onto Whatman 903® cards and analyzed using ultra-high performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS). The DBS concentrations measured were compared with serum concentrations analyzed using standard laboratory methods. The paired DBS and serum samples were obtained from ICU. Deming regression and Bland-Altman difference plot were used to assess the consistency between the two methods. The DBS method was validated including selectivity, carryover, precision (0.078-16.70 %), accuracy (85.19-117.17 %), matrix effect, recovery (46.51 %-114.15 %), linearity, and dilution integrity. DBS samples stability at -80 °C for at least 30 days. DBS and serum concentrations of two antibiotics were compared, and statistical analysis confirmed good correlation (r > 0.97) between them. This study provides a new approach to TDM, suggesting that DBS may replace or complement traditional analytical sampling techniques. It has been validated for guiding individualized antimicrobial therapy in ICU patients.
2025-08-01RESPIRATORY MEDICINE
Antibiotic for community-acquired pneumonia in hospitalized adults: A systematic review and Bayesian network meta-analysis
Review
作者: Hu, Cong ; Gao, Feng ; Li, Yonglin ; Tan, Zhanpeng ; Li, Guowei ; Chen, Dunfan
BACKGROUND:
Inconsistent results have been obtained with various antibiotics for community-acquired pneumonia (CAP) in hospitalized adults. We performed a Bayesian network meta-analysis to compare and rank the effectiveness of antibiotics for adult patients with CAP.
METHODS:
The databases of PubMed, Embase, and the Cochrane library were systematically searched until May 2025, for randomized controlled trials (RCTs) comparing at least two antibiotics for hospitalized adults with CAP. The investigated outcomes included clinical failure, bacteriological failure, mortality, total adverse events, gastrointestinal events, and requiring discontinuation of treatment.
RESULTS:
Forty RCTs involving 12,838 hospitalized adults with CAP were selected for the final meta-analysis. The surface under the cumulative ranking probabilities (Surface Under the Cumulative Ranking Area, SUCRA; higher values indicate a greater likelihood of a treatment being the most effective) found that trovafloxacin (SUCRA: 87 %) and teicoplanin (SUCRA: 85 %) provided relatively better effects on clinical failure. Clarythromycin-ceftriaxone (SUCRA: 77 %) had the best effect for risk of bacteriological failure. Amoxicillin-clavulanate provided the optimal effect for reducing the risk of mortality (SUCRA: 82 %). The risk of total adverse events was lowest on using doxycycline (SUCRA: 86 %). Doxycycline (SUCRA: 89 %) and omadacycline (SUCRA: 80 %) provided relatively lower risk of gastrointestinal events. Finally, the use of ciprofloxacin was associated with the lowest risk of requiring discontinuation of treatment (SUCRA: 77 %).
CONCLUSIONS:
This study provided an overview of the optimal antibiotics in management of adult patients with CAP, based on treatment effectiveness and safety profiles.
100 项与 替考拉宁 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 囊性纤维化 | 临床1期 | 意大利 | 2019-10-25 | |
| 囊性纤维化 | 临床1期 | 意大利 | 2019-10-25 | |
| 埃博拉病毒性疾病 | 临床前 | 中国 | 2016-04-01 | |
| 严重急性呼吸综合征 | 临床前 | 中国 | 2016-04-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | antistaphylococcal drugs (Group 1 (positive initial BC for S.aureus)) | 積憲壓鏇積選鬱選顧鹽(網齋鏇繭鏇糧鑰窪夢糧) = 鬱糧廠構廠糧壓蓋齋窪 獵積範憲夢觸夢廠蓋襯 (簾艱構鬱憲獵觸鏇鏇繭 ) 更多 | - | 2024-02-23 | ||
antistaphylococcal drugs (Group 2 (negative BC for S.aureus)) | 積憲壓鏇積選鬱選顧鹽(網齋鏇繭鏇糧鑰窪夢糧) = 蓋憲觸觸膚築構選簾膚 獵積範憲夢觸夢廠蓋襯 (簾艱構鬱憲獵觸鏇鏇繭 ) 更多 | ||||||
N/A | 190 | Aerobic antibiotics | 網窪遞積遞壓網願壓餘(蓋襯範蓋鏇壓壓鹽繭蓋) = 繭築鬱齋獵齋遞鏇窪鏇 壓觸遞選願鏇獵蓋願淵 (遞廠範夢鹽繭齋憲構憲 ) | - | 2021-06-09 | ||
N/A | - | - | Cefuroxime 1.5g | 衊鏇齋糧鏇餘蓋觸範築(築餘遞網淵廠積顧夢製) = 積觸鬱願衊憲淵積顧觸 壓製簾觸範築積鹽蓋淵 (簾餘製廠鏇憲積鬱廠遞 ) 更多 | 积极 | 2013-09-01 | |
Flucloxacillin (or teicoplanin) and gentamicin | 衊鏇齋糧鏇餘蓋觸範築(築餘遞網淵廠積顧夢製) = 築糧憲範淵醖鹹壓艱艱 壓製簾觸範築積鹽蓋淵 (簾餘製廠鏇憲積鬱廠遞 ) 更多 | ||||||
临床4期 | 44 | Teicoplanin lock therapy | 簾鏇築積糧襯鹽襯繭選(窪顧鹹願觸夢鬱觸鏇蓋) = 鑰窪鹽範齋簾窪鏇憲糧 繭壓蓋積齋鹽選糧膚觸 (膚觸襯壓築簾獵範衊遞 ) 更多 | 积极 | 2009-11-01 | ||
Vancomycin lock therapy | 簾鏇築積糧襯鹽襯繭選(窪顧鹹願觸夢鬱觸鏇蓋) = 觸簾構築餘膚遞願鬱觸 繭壓蓋積齋鹽選糧膚觸 (膚觸襯壓築簾獵範衊遞 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
生物类似药
生物类似药在不同国家/地区的竞争态势。请注意临床1/2期并入临床2期，临床2/3期并入临床3期
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用